- 1. DOPA decarboxylase
- [One of the AROMATIC-L-AMINO-ACID DECARBOXYLASES, this enzyme is responsible for the conversion of dopa to dopamine. It is of clinical importance in the treatment of Parkinson's disease. EC 4.1.1.28. ( MSH )] (UMLS (CSP) C0003806) =Amino Acid, Peptide, or Protein; Enzyme
| - 14. Dopamine Receptor D2 A2 Allele
- [Human DRD2 Gene at 11q23 encodes Dopamine Receptor D2, a G-protein coupled receptor that inhibits adenylyl cyclase activity. Missense mutation in DRD2 causes myoclonus dystonia; other mutations have been associated with schizophrenia. Alternative splicing results in two different isoforms. A third variant has been described, but it has not been determined whether this form is normal or due to aberrant splicing. Different alleles are associated with increased incidence of substance abuse. (NCI) ( NCI )] (UMLS (NCI) C1333252) DRD2 2 Allele;
DRD2 A2 Allele;
=Gene or Genome ;
|
- 2. DOPA decarboxylase inhibitor
- [ ] (UMLS (CSP) C0598272) =Organic Chemical; Pharmacologic Substance ;
| - 15. Dopamine Receptor D2 Gene
- [This gene plays an inhibitory role in the regulation of adenylyl cyclase activity. ( NCI )] (UMLS (NCI) C1333253) DRD2;
DRD2 Gene;
=Gene or Genome ;
|
- 3. DOPAC
- [A deaminated metabolite of LEVODOPA. ( MSH )] (UMLS (CSP) C0000376) =Organic Chemical; Biologically Active Substance ;
| - 16. Dopamine Receptor D4 Gene
- [This gene plays a role in G protein-coupled receptor signal transduction and inhibits adenylyl cyclase activity. ( NCI )] (UMLS (NCI) C1333254) DRD4;
DRD4 Gene;
=Gene or Genome ;
|
- 4. Dopaflex
- (UMLS (NCI) C1449995) =Amino Acid, Peptide, or Protein; Pharmacologic Substance
| - 17. Dopamine Receptor D5 Gene
- [This gene plays a regulatory role in adenylate cyclase activity and intracellular cAMP store accumulation. The gene is thought to act as a stimulus in both activities. ( NCI )] (UMLS (NCI) C1333255) DRD5;
DRD5 Gene;
=Gene or Genome ;
|
- 5. Dopamet
- (UMLS (NCI) C0591404) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;
| - 18. dopamine uptake complex
- [A dopamine plasma membrane transporter protein complex located on the membrane of dopaminergic neurons. The complex includes homo-oligomers of the DAT Dopamine Transporter. ( MSH )] (UMLS (CSP) C0114839) =Amino Acid, Peptide, or Protein; Receptor ;
|
- 6. dopamine
- [one of the catecholamine neurotransmitters in the brain; it is derived from tyrosine and is the precursor to norepinephrine and epinephrine; dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement; dopamine receptors mediate its action. ( CSP )] (UMLS (CSP) C0013030) =Organic Chemical; Pharmacologic Substance; Neuroreactive Substance or Biogenic Amine =catecholamine;
Neurotransmitter;
Dopamine Agonist;
[AU100] SYMPATHOMIMETICS (ADRENERGICS) =DARPP;
DOPAMINE HYDROCHLORIDE;
| - 19. Doppler blood flow measurement
- [ ] (UMLS (CSP) C0599582) =Diagnostic Procedure ;
|
- 7. Dopamine Agonist
- [class of drugs and natural products which enhance dopaminergic function by increasing dopamine biosynthesis, decreasing dopamine degradation or reuptake, or interacting positively with dopamine receptors. ( CSP )] (UMLS (NCI) C0178601) =Pharmacologic Substance =neuropharmacologic agent;
neurotransmitter agonist;
Dopamine Receptor Interactions;
=apomorphine;
2-Bromo-alpha-ergocryptine;
cocaine;
dihydroxyphenylalanine;
dopamine;
PERGOLIDE;
FENOLDOPAM | - 20. Doppler blood flowmeter
- [ ] (UMLS (CSP) C0599583) =Manufactured Object ;
|
- 8. Dopamine Antagonist
- [class of drugs and natural products which inhibit dopaminergic function by decreasing dopamine biosynthesis, increasing dopamine degradation or reuptake, or interacting negatively with dopamine receptors. ( CSP )] (UMLS (NCI) C0242702) =Pharmacologic Substance; Neuroreactive Substance or Biogenic Amine =catecholamine inhibitor;
Dopamine Receptor Interactions =methylphenyltetrahydropyridine;
4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone;
raclopride;
SCH 23390;
2,4,5-Trihydroxyphenethylamine | - 21. Doppler Echocardiography
- [A procedure that uses sound waves to measure characteristics of disturbed bood flow, such as direction, velocity and turbulence. This enables the examiner to differentiate between normal and abnormal flow patterns and, in some cases, to quantitate those characteristics that are helpful in determining the severity of abnormal flow states. ( NCI )] (UMLS (NCI) C0013520) =Diagnostic Procedure ;
|
- 9. dopamine hydroxylase inhibitor
- [any substance or agent which suppresses, prevents or opposes the action of dopamine hydroxylase which catalyzes the biosynthesis of norepinephrine from dopamine. ( CSP )] (UMLS (CSP) C0596457) =Pharmacologic Substance =oxidoreductase inhibitor;
| - 22. Doppler OCT
- [Optical Coherence Tomography (OCT) combines the principles of ultrasound with the imaging performance of a microscope. OCT uses infrared light waves that reflect off the internal microstructure within the biological tissues. The frequencies and bandwidths of infrared light are orders of magnitude higher than medical ultrasound signals, resulting in greatly increased image resolution, 8-25 times greater than any existing modality. In addition to providing high-level resolutions for the evaluation of microanatomic structures OCT is also able to provide information regarding tissue composition. ( NCI )] (UMLS (CSP) C0920367) Optical Coherence Tomography =Diagnostic Procedure ;
|
- 10. dopamine receptor
- [family of G protein-coupled receptors of two general classes: D1 (- A, -B) stimulation increases intracellular cAMP, whereas D2, D3, or D4 stimulation decreases cAMP, increases K+ flux, or decreases Ca++ flux. ( CSP )] (UMLS (CSP) C0034798) =Amino Acid, Peptide, or Protein; Receptor ;
=neurotransmitter receptor;
| - 23. Doppler Ultrasound
- [Diagnostic imaging that uses sound waves (ultrasound) applying the Doppler effect, with frequency-shifted ultrasound reflections produced by moving targets (usually red blood cells) in the bloodstream along the ultrasound axis in direct proportion to the velocity of movement of the targets, to determine both direction and velocity of blood flow. ( NCI )] (UMLS (NCI) C0162481) =Diagnostic Procedure
|
- 11. Dopamine Receptor D1
- [Dopamine Receptor D1, encoded by the human DRD1 gene, is the most abundant dopamine receptor in the central nervous system. This G-protein coupled receptor stimulates adenylyl cyclase and activates cyclic AMP-dependent protein kinases. It regulates neuronal growth and development, mediates some behavioral responses, and modulates dopamine receptor D2-mediated events. Alternate transcription initiation sites result in two transcript variants of this gene. (From LocusLink and NCI) ( NCI )] (UMLS (NCI) C1367800) DRD1;
DRD1 Protein =Amino Acid, Peptide, or Protein; Receptor | - 24. Doppler velocimetry
- [ ] (UMLS (CSP) C0598596) =Natural Phenomenon or Process
|
- 12. Dopamine Receptor D1 Gene
- [This gene is involved in the regulation of dopamine receptor transport and neuronal signal transduction pertaining to neuronal growth and development. ( NCI )] (UMLS (NCI) C1333250) DRD1;
DRD1 Gene;
=Gene or Genome ;
| - 25. Dopram
- (UMLS (NCI) C0699979) =Organic Chemical; Pharmacologic Substance ;
|
- 13. Dopamine Receptor D2 A1 Allele
- [Human DRD2 Gene at 11q23 encodes Dopamine Receptor D2, a G-protein coupled receptor that inhibits adenylyl cyclase activity. Missense mutation in DRD2 causes myoclonus dystonia; other mutations have been associated with schizophrenia. Alternative splicing results in two different isoforms. A third variant has been described, but it has not been determined whether this form is normal or due to aberrant splicing. Different alleles are associated with increased incidence of substance abuse. The A1 allele has been associated with alcoholism. (NCI) ( NCI )] (UMLS (NCI) C1333251) DRD2 1 Allele;
DRD2 A1 Allele;
=Gene or Genome ;
| |
home
